Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Innovent Adds Second ADC to Collaboration with Synaffix, an ADC CRO

publication date: Dec 7, 2023

Suzhou Innovent Biologics will expand its partnership with Synaffix, a Lonza company (SIX:LONN), using the company’s technology to develop at least one antibody-drug conjugate (ADC) candidate. In 2021, Innovent employed Synaffix's ADC technologies to develop IBI343, a CLDN18.2 ADC, which is now in a Phase 1 trial. Innovent will be responsible for all development for the new new ADC candidates, while Synaffix is eligible to receive an upfront payment plus potential milestones and royalties on commercial sales for each licensed target. Details were not disclosed. Earlier this year, Lonza paid 100 million euros to acquire Synaffix, an Amsterdam company. More details....

Stock Symbol: (HK: 01801)

Share this with colleagues: